Treatment of idiopathic pulmonary fibrosis (IPF) with Esbriet (pirfenidone) increased five-year survival, and also resulted in less decline…
Articles by José Lopes, PhD
Evaluating the lung area that is normal, or healthy, can help predict the survival of patients with combined pulmonary fibrosis…
A Phase 1 trial of an investigational treatment for idiopathic pulmonary fibrosis (IPF), PLN-74809, has dosed a first group of…
Throughout 2018, Pulmonary Fibrosis News provided you daily coverage of key discoveries, potential treatments, and clinical trials related to pulmonary…
Sustained-release capsules of Ofev (nintedanib), which is used to treat idiopathic pulÂmonary fibrosis (IPF), were better at reaching systemic…
The nasal epithelium of patients with idiopathic pulmonary fibrosis (IPF) shows different levels of gene expression implicated in inflammatory…
Bridge Biotherapeutics filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to start…
Redx Pharma announced it soon give an update on early work on a potentially new type of idiopathic pulmonary…
Treatment of idiopathic pulmonary fibrosis (IPF) with Esbriet (pirfenidone) leads to stable lung function over two years, according…
FibroGen’s investigational compound pamrevlumab has received fast track designation by the U.S. Food and Drug Administration (FDA) for…